Stanford University


Showing 821-840 of 2,212 Results

  • Gentaro Ikeda

    Gentaro Ikeda

    Instructor, Medicine - Cardiovascular Medicine

    BioDr. Ikeda is a physician-scientist who develops innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on his clinical experience as a cardiologist, he has become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including β-blockers, ivabradine, and renin-angiotensin-aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, he moved to academia to conduct translational research. During his graduate training in the Egashira Lab, he focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. He obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. He realized the importance of translational research and the great potential of DDS to overcome many clinical problems. He developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. He published a first-author paper and received academic awards for his novel science. Since becoming a postdoctoral fellow in the Yang Lab, he has continued to build upon his previous training in translational research. He is currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for mitochondria-related diseases such as heart failure and mitochondrial disease.

  • Fumiaki Ikeno

    Fumiaki Ikeno

    Program Director (U.S) Japan Biodesign, Stanford Biodesign, Medicine - Med/Cardiovascular Medicine

    BioProgram Director (U.S) Japan Biodesign, Stanford Biodesign
    Researcher Cardiovascular Medicine, Stanford University
    Faculty of Japan Reach, CARE (Center for Asian Health Research and Education) , Stanford University
    Co-Director of Asia, SPARK Global, Stanford SPARK , Stanford University


    Dr. Ikeno is a Researcher, Cardiovascular Medicine, Stanford University. In this role, he is responsible for pre clinical studies including GLP for medical devices and also regenerative medicines for cardiovascular diseases. Currently, he is devoting himself to the international regulatory project between Japan and the United States, also known as "Harmonization by Doing", whose focus is to collaborate with regulatory agencies such as FDA, PMDA/MHLW, academia and industries for improving the regulatory process in the 2 largest medtech markets. Dr. Ikeno also devoted himself to found Japan biodesign program which is a collaborative program with University of Tokyo, Osaka University, Tohoku University, Japan Federation Medical Device Association, Ministry of Education Japan and Stanford biodesign program. Currently, Dr. Ikeno serves as the Program Director (US) for Japan Biodesign. Dr. Ikeno is co-founder and board member of US-Japan MedTech Frontier which is a non-profit cooperate to make a trans-pacific eco-system of medical device between Japan and USA.

    After 9 years clinical practice as an interventional cardiologist and Family Doctor in rural areas of Japan, Dr. Ikeno came to Stanford as a Researcher and completed his Biodesign Certificate Program. Being part of the ecosystem in Silicon Valley, Dr. Ikeno participated in more than 200 medtech projects and 50 GLP studies as well as in the analysis of clinical trials for cardiovascular medicine (BARI2D, FAME, ReOPEN etc). His other academic consortium projects include Peripheral Academic Research Consortium, Global Consensus Working Group of Optical Coherence Tomography, and Japan-US consensus document for the treatment of critical limb ischemia.

    Over the last decade, Dr. Ikeno has served as an advisor for medical device industries and currently serves as a chief medical officer of an incubation fund specific for medtech (Medventure Partners, Inc, Tokyo) as a spin-off from Innovation Network Corporation of Japan (INCJ) that is the largest government and private partnership fund in Japan. He is also serving as a chair of cardiovascular working group of APAN (Asian Pacific Advanced Network) that contributes the remote education, research activities, and tele-health using a specialized internet network. Dr.Ikeno is also serving as consulting faculty/lecturer roles in several universities in Japan including University of Tokyo, Osaka University, Tsukuba University etc. Dr. Ikeno has authored over 70 peer reviewed publications and textbooks and has been invited to lecture at international medical conferences. Dr. Ikeno is a council member of U.S.- Japan Council which is a non-profit organization by Japanese American. He is serving as a mentor for START-X MED which is an accelerating program for Stanford related entrepreneurs in medical fields.

    Contact Information


    Falk CVRC CV007
    300 Pasteur Drive
    Palo Alto, CA 94305-5406

  • Hiroyuki Inoue

    Hiroyuki Inoue

    Postdoctoral Scholar, Cardiovascular Medicine

    BioDr. Inoue is a physician-scientist who is enthusiastic about bridging research findings and clinical practice.
    - a board certified cardiologist with 10+ years clinical experience
    - experience in 400+ cases as a main operator in percutaneous coronary intervention, catheter ablation, and cardiac device implantation
    - research expertise primarily in iPSCs, genome editing, and regenerative medicine

    Dr. Inoue joined the Yang lab in 2022. His research aim is the development of novel regenerative therapeutics for heart failure.

  • John P.A. Ioannidis

    John P.A. Ioannidis

    Professor of Medicine (Stanford Prevention Research), of Epidemiology and Population Health and by courtesy of Biomedical Data Science

    Current Research and Scholarly InterestsMeta-research
    Evidence-based medicine
    Clinical and molecular epidemiology
    Human genome epidemiology
    Research design
    Reporting of research
    Empirical evaluation of bias in research
    Randomized trials
    Statistical methods and modeling
    Meta-analysis and large-scale evidence
    Prognosis, predictive, personalized, precision medicine and health
    Sociology of science

  • Eric Ip

    Eric Ip

    Clinical Professor, Medicine - Primary Care and Population Health

    Current Research and Scholarly InterestsMy research interests include the use and abuse of anabolic steroids and other performance enhancing/cognitive enhancing drugs.

  • Haruka Itakura, MD, PhD

    Haruka Itakura, MD, PhD

    Assistant Professor of Medicine (Oncology)

    BioDr. Haruka Itakura is an Assistant Professor of Medicine (Oncology) in the Stanford University School of Medicine, a data scientist, and a practicing breast medical oncologist at the Stanford Women’s Cancer Center. She is board-certified in Oncology, Clinical Informatics, Hematology, and Internal Medicine. Her research mission is to drive medical advances at the intersection of cancer and data science, applying state-of-the-art machine learning/artificial intelligence techniques to extract clinically actionable knowledge from heterogeneous multi-scale cancer data to improve patient outcomes. Her ongoing research to develop robust methodologies and apply cutting-edge techniques to analyze complex cancer big data was catapulted by an NIH K01 Career Development Award in Biomedical Big Data Science after obtaining a PhD in Biomedical Informatics at Stanford University. Her cancer research focuses on extracting radiomic (pixel-level quantitative imaging) features of tumors from medical imaging studies and applying machine learning frameworks, including radiogenomic approaches, for the integrative analysis of heterogeneous, multi-omic (e.g., radiomic, genomic, transcriptomic) data to accelerate discoveries in cancer diagnostics and therapeutics. Her current projects include prediction modeling of survival, treatment response, recurrence, and CNS metastasis in different cancer subtypes; detection of occult invasive breast cancer; and identification of novel therapeutic targets. Her ultimate goal is to be able to translate her research findings back to the clinical setting for the benefit of patients with difficult-to-treat cancers.

  • Charlotte D. Jacobs M.D.

    Charlotte D. Jacobs M.D.

    Drs. Ben and A. Jess Shenson Professor in the School of Medicine, Emerita

    Current Research and Scholarly InterestsClinical Interests: general oncology, sarcomas. Research Interests: clinical trials in solid tumors.

  • Karen Blake Jacobson

    Karen Blake Jacobson

    Adjunct Clinical Assistant Professor, Medicine

    BioDr. Jacobson is Postdoctoral Medical Fellow in the Division of Infectious Diseases and Geographic Medicine. She previously received her MD and MPH from Icahn School of Medicine at Mount Sinai and completed residency in Internal Medicine/HIV Primary Care at Yale. She is board certified in Internal Medicine and Infectious Diseases. Dr. Jacobson’s current research focus is on the epidemiology and natural history of SARS-CoV-2, and the interactions between SARS-CoV-2 and malaria in pregnancy in malaria endemic settings.

  • Prasanna Jagannathan

    Prasanna Jagannathan

    Assistant Professor of Medicine (Infectious Diseases) and of Microbiology and Immunology

    BioI am an Infectious Diseases physician-scientist with a research program in human immunology of malaria and clinical trials of immune modulatory interventions. Our group has been conducting detailed longitudinal cohort studies in children and pregnant women in order to study how repeated malaria shapes the cellular immune response. We are also studying how malaria control interventions such as antimalarial chemoprevention and vector control shape the acquisition and/or maintenance of protective immunity to malaria. We have expanded this work to not only include studying the mechanisms driving naturally acquired immunity to malaria, but other infectious diseases, including SARS CoV-2. We have also lead and/or participated in studies evaluating therapeutic strategies for patients with mild to moderate COVID-19.

  • Fereshteh Jahanbani

    Fereshteh Jahanbani

    Basic Life Research Scientist, Medicine - Med/Immunology & Rheumatology

    BioDr. Jahanbani received her PharmD from Tehran University of Medical Sciences (TUMS) and PhD in pharmacology from Iran University of Medical Sciences (IUMS) and her postdoctoral degree from Case Western Reserve University (CWRU) and University of California, Santa Cruz (UCSC). She joined Stanford Center for Genomics and Personalized Medicine in June 2012. Her work is focused on better understanding the etiology of chronic complex conditions and multi-morbidity using multi-omics and precision health approaches. She has been leading ME/CFS related disorders multi-omics study combining the power of both family and population approaches and also cofounded “Research To The People at Stanford Program”.